Nov 18 (Reuters) - MBX Biosciences Inc MBX.O:
MBX BIOSCIENCES ANNOUNCES LAST SUBJECT LAST VISIT IN PHASE 1 TRIAL OF MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA
MBX BIOSCIENCES : LOOK FORWARD TO SHARING FULL-TOPLINE RESULTS OF MBX 1416 PROGRAM IN EARLY JANUARY 2025
Source text: ID:nGNX5yFt0s
Further company coverage: MBX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.